QuadraMune Composition Stimulating NK Cell Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective stimulation of natural killer (NK) cell activity, particularly for therapeutic applications against inflammatory and immunological parameters in COVID-19 patients.
Innovation Solution
A therapeutic combination of Green Tea extract (epigallocatechin-3-gallate or analogue), Blueberry extract (pterostilbene or analogue), Nigella Sativa extract (thymoquinone or analogue), and Broccoli extract (sulforaphane or analogue) is administered with or without metformin to stimulate NK cell activity, enhancing cytokine production and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional single-agent therapies are used to stimulate NK cell activity, then treatment simplicity is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines five distinct nutraceutical agents (Green Tea extract, Blueberry extract, Nigella Sativa extract, Broccoli extract, and metformin) into a single therapeutic composition called QuadraMune. This merging approach achieves synergistic stimulation of NK cell activity, where the combination produces greater therapeutic efficacy than any single agent alone, while still being administered as one integrated treatment protocol
Solution Approach 2:
The invention creates a composite nutraceutical formulation that integrates multiple bioactive compounds from different natural sources. Each component contributes specific immunomodulatory properties: Green Tea (EGCG) provides antioxidant support, Blueberry (pterostilbene) enhances NK cell function, Nigella Sativa (thymoquinone) stimulates cytokine production, Broccoli (sulforaphane) supports immune cell activity, and metformin provides metabolic modulation. This composite approach delivers comprehensive immune stimulation through a single therapeutic agent
2Reliability
If no nutraceutical intervention is used, then treatment simplicity is maintained, but NK cell activity remains insufficient for therapeutic effect
Solution Approach 1:
The patent employs preliminary action by administering nutraceutical agents that prepare and prime the immune system before viral infection or during early disease stages. The QuadraMune composition pre-stimulates NK cell activity and enhances cytokine production pathways, creating a heightened immune state that responds more effectively to subsequent viral challenges or cancer cell encounters
Solution Approach 2:
The nutraceutical composition acts as an intermediary substance that mediates between the administered treatment and the immune system's NK cells. Rather than directly attacking viruses or cancer cells, the formulation uses bioactive compounds to signal and stimulate NK cells, which then perform the actual antiviral and antitumor functions. This intermediary approach enhances immune system autonomy while providing therapeutic benefit
Data Source
AI summary
Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of pterostilbene, Nigella sativa extract, green tea extract, and broccoli. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.